Search results
Results From The WOW.Com Content Network
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Cytokine. Cytokines are a broad and loose category of small proteins (~5–25 kDa [1]) important in cell signaling. Due to their size, cytokines cannot cross the lipid bilayer of cells to enter the cytoplasm and therefore typically exert their functions by interacting with specific cytokine receptors on the target cell surface.
Ciliate undergoing cytokinesis, with the cleavage furrow being clearly visible. Cytokinesis ( / ˌsaɪtoʊkɪˈniːsɪs /) is the part of the cell division process and part of mitosis during which the cytoplasm of a single eukaryotic cell divides into two daughter cells. Cytoplasmic division begins during or after the late stages of nuclear ...
Shares of the San Francisco-based Cytokinetics surged over 80% to touch a more than a 19-year high of $83.82, on track to add as much as $3.74 bi Cytokinetics heart drug succeeds in closely ...
James A. Spudich ( / ˈspʊdɪtʃ / [1]) is an American scientist and professor. He is the Douglass M. and Nola Leishman Professor of Biochemistry and of Cardiovascular Disease at Stanford University and works on the molecular basis of muscle contraction. He was awarded the Albert Lasker Basic Medical Research Award in 2012 with Michael Sheetz ...
Interleukin 3 is an interleukin, a type of biological signal ( cytokine) that can improve the body's natural response to disease as part of the immune system. [10] In conjunction with other β common chain cytokines GM-CSF and IL-5, IL-3 works to regulate the inflammatory response in order to clear pathogens by changing the abundance of various ...
Aficamten. Aficamten ( CK-274) is a cardiac myosin inhibitor [1] developed by Cytokinetics for the treatment of obstructive hypertrophic cardiomyopathy. [2] [3] [4]
Omecamtiv mecarbil. Omecamtiv mecarbil ( INN [1] ), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is an experimental drug being studied for a potential role in the treatment of left ventricular systolic heart failure. [2] Systolic heart failure involves a loss of effective actin -myosin cross bridges in the ...